Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119916 | 1.00 | HCAR3 (0.40) | HCAR3KCNMA1L3MBTL1MAPK1MAPT | |
| SCHEMBL23119912 | 0.89 | HCAR3 (0.40) | HCAR3KCNMA1L3MBTL1MAPK1MAPT | |
| SCHEMBL19540705 | 0.85 | MAPT (0.39) | KCNMA1L3MBTL1MAPK1MAPTTDP1 | |
| SCHEMBL20956857 | 0.82 | HDAC1 (0.40) | — | |
| SCHEMBL20956830 | 0.82 | HDAC1 (0.40) | — | |
| SCHEMBL20956856 | 0.82 | HDAC1 (0.40) | — | |
| SCHEMBL20956800 | 0.82 | HCAR3 (0.45) | HCAR3KCNMA1L3MBTL1MAPK1MAPT | |
| SCHEMBL20956752 | 0.80 | L3MBTL1 (0.40) | HCAR3KCNMA1L3MBTL1MAPK1MAPT | |
| SCHEMBL20956754 | 0.80 | L3MBTL1 (0.40) | HCAR3KCNMA1L3MBTL1MAPK1MAPT | |
| SCHEMBL20956804 | 0.80 | HCAR3 (0.39) | HCAR3KCNMA1L3MBTL1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135794-A1 | BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST | MEDSHINE DISCOVERY INC. (CN) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135794-A1 | BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST | BIRC2, BIRC5, BIRC8 | HCAR3 1457/4885KCNMA1 332/4885L3MBTL1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.